Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXC-2023 MAD study in healthy volunteers
NCT03542435Phase 1Completed
- Sponsor
- Promentis Pharmaceuticals, Inc.
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in trichotillomania (TTM) and obsessive compulsive disorder (OCD) comparing SXC-2023 with Placebo (2 arms). Primary endpoint: Treatment related adverse events at 18 days. Started Apr 2018; status: completed.
02
Drugs
SXC-2023
03
Conditions
trichotillomania (TTM)obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT03542435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542435.